March 28, 2023
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference
March 23, 2023
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
March 8, 2023
Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences
March 6, 2023
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
February 1, 2023
Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
January 31, 2023
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
January 5, 2023
Athira Pharma Provides 2023 Pipeline Outlook
December 21, 2022
Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
December 5, 2022
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
December 1, 2022
Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
Displaying 41 - 50 of 139